BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38135849)

  • 1. Theranostic role of
    Yang Q; Chen Z; Qiu Y; Huang W; Wang T; Song L; Sun X; Li C; Xu X; Kang L
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1246-1260. PubMed ID: 38135849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Theranostic Efficacy of
    Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
    Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the theranostic potential of
    Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
    EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
    J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Huang Y; Yang Z; Li F; Zhao H; Li C; Yu N; Hamilton DJ; Li Z
    J Med Chem; 2021 Mar; 64(5):2705-2713. PubMed ID: 33646782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
    Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
    Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of [
    Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy.
    Magro N; Oteo M; Romero E; Ibáñez-Moragues M; Lujan VM; Martínez L; Vela O; López-Melero ME; Arroyo AG; Garaulet G; Martínez-Torrecuadrada JL; Mulero F; Morcillo MA
    Nucl Med Biol; 2024 May; 136-137():108930. PubMed ID: 38833768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
    Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
    J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Evaluation of Multidrug Resistance via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.
    Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
    Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
    Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
    J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J N